Metronidazole for Bacterial Vaginosis
For non-pregnant women with bacterial vaginosis, treat with metronidazole 500 mg orally twice daily for 7 days, which is the most effective first-line regimen with cure rates of approximately 95%. 1
Treatment Regimens for Non-Pregnant Women
Recommended First-Line Options (Equally Efficacious)
- Metronidazole 500 mg orally twice daily for 7 days (preferred for highest efficacy)
- Metronidazole gel 0.75%, one full applicator (5 g) intravaginally once daily for 5 days
- Clindamycin cream 2%, one full applicator (5 g) intravaginally at bedtime for 7 days
The oral metronidazole 7-day regimen achieves 95% cure rates compared to 84% for single-dose therapy 2. The vaginal clindamycin cream is less efficacious than metronidazole regimens 1.
Alternative Regimens (Lower Efficacy)
- Metronidazole 2 g orally as a single dose (lower efficacy, use only when adherence is a concern)
- Clindamycin 300 mg orally twice daily for 7 days
- Clindamycin ovules 100 g intravaginally once at bedtime for 3 days
Critical Patient Counseling
Patients must avoid all alcohol during metronidazole treatment and for 24 hours after completion to prevent disulfiram-like reactions (abdominal cramps, nausea, vomiting, headaches, flushing) 1, 3. Clindamycin cream and ovules are oil-based and may weaken latex condoms and diaphragms 1.
Treatment in Pregnancy
All symptomatic pregnant women must be tested and treated due to associations with premature rupture of membranes, preterm labor, preterm birth, and postpartum endometritis 1.
Pregnancy Treatment Regimens
- Metronidazole 250 mg orally three times daily for 7 days (recommended)
- Clindamycin 300 mg orally twice daily for 7 days (alternative)
Avoid topical agents during pregnancy—evidence from three trials suggests increased adverse events (prematurity, neonatal infections) with clindamycin cream 1. Multiple studies and meta-analyses have not demonstrated teratogenic or mutagenic effects from metronidazole use during pregnancy 1, 4.
For asymptomatic pregnant women at high risk for preterm delivery (prior premature infant), screening and treatment at the first prenatal visit may reduce preterm delivery based on three of four randomized trials 1.
Special Considerations
Allergy or Intolerance
If metronidazole allergy or intolerance exists, use clindamycin cream or oral clindamycin 1. Metronidazole gel can be considered for patients who don't tolerate systemic metronidazole, but patients allergic to oral metronidazole should never receive metronidazole vaginally 1.
Recurrent BV
Recurrence is common—up to 50% within one year 5. For recurrent disease:
- Use an extended course: metronidazole 500 mg twice daily for 10-14 days 5
- If ineffective: metronidazole vaginal gel 0.75% for 10 days, then twice weekly for 3-6 months 5
- Any recommended regimen can be used for recurrent episodes 1
No long-term maintenance regimen is recommended 1.
Partner Management
Do not routinely treat sexual partners—clinical trials show no effect on treatment response or recurrence rates 1.
Follow-Up
Follow-up visits are unnecessary if symptoms resolve 1. Advise patients to return if symptoms recur. For pregnant women, consider follow-up evaluation at 1 month after treatment completion to verify cure 4.
Common Pitfalls to Avoid
- Don't use single-dose metronidazole 2 g as first-line therapy—it has significantly lower efficacy (84% vs 95%) 2
- Don't forget alcohol counseling—this is a critical safety issue that causes treatment-related adverse events 3
- Don't use topical agents in pregnancy—systemic therapy is preferred and safer 1
- Don't treat asymptomatic partners—this provides no clinical benefit 1
- Don't use clindamycin cream as first-line—it's less efficacious than metronidazole regimens 1
Mechanism and Pharmacology
Metronidazole has direct bactericidal activity against anaerobic bacteria with MIC ≤1 mcg/mL for most BV-associated organisms 3. Peak plasma concentrations occur 1-2 hours after oral administration, with an 8-hour half-life 3. The drug achieves therapeutic concentrations in vaginal tissues and reduces genital inflammation primarily by eliminating BV-associated bacteria rather than increasing lactobacilli 6.